



Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty Docket No.
28341/6114.NSerial No.
09/809,524Applicant
Lowery *et al.*Filing Date
March 15, 2001Group
1845

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)







U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	4,877,612	10-31-89	Berger <i>et al.</i>	424	92	
	A2	5,876,931	03-02-99	Holden, David W.	435	6	

RECEIVED



JUN 07 2002

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation	
							Yes	No
	B1	EP 109 942 B1	03-06-91	EPO	—	—		
	B2	EP 180 564 B1	07-17-91	EPO	—	—		
	B3	EP 231 039 B1	01-08-92	EPO	—	—		
	B4	EP 0 796 341 B1	09-23-98	EPO	—	—		
	B5	GB-A-2 189 141	10-21-87	GB	—	—		
	B6	WO 96/17951	06-16-96	WIPO	—	—		

TECH CENTER 600/291

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

	C1	Cardenas <i>et al.</i> , Oral Immunization Using Live Attenuated <i>Salmonella</i> spp. as Carriers of Foreign Antigens, <i>Clin Microbial Rev.</i> 5:328-342 (1992).
	C2	Chatfield <i>et al.</i> , Live <i>Salmonella</i> as Vaccines and Carriers of Foreign Antigenic Determinants, <i>Vaccine</i> 7:495-498 (1989).

EXAMINER

MARK NAVARRO

DATE CONSIDERED

10/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6114.NSerial No.
09/809,524Applicant
Lowery *et al.*Filing Date
March 15, 2001Group
1643

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

✓	C3	Clarke <i>et al.</i> , Vaccination of Calves with a Diaminopimelic Acid Mutant of <i>Salmonella typhimurium</i> , <i>Can J Vet Res.</i> 51:32-38 (1987).
✓	C4	Curtiss <i>et al.</i> , Nonrecombinant and Recombinant Avirulent <i>Salmonella</i> Live Vaccines for Poultry, in Blankenship <i>et al.</i> , eds., Colonization control of human bacterial enteropathogens in poultry, Academic Press, New York, pp. 169-198 (1991).
✓	C5	Curtiss <i>et al.</i> , Recombinant Avirulent <i>Salmonella</i> for Oral Immunization to Induce Mucosal Immunity to Bacterial Pathogens, in Kohler <i>et al.</i> , eds., Vaccines: new concepts and developments. Proceedings of the 10th Int'l Convocation of Immunology, Longman Scientific and Technical, Harlow, Essex, UK, pp. 261-271 (1987).
✓	C6	Curtiss, Attenuated <i>Salmonella</i> Strains as Live Vectors for the Expression of Foreign Antigens, in Woodrow <i>et al.</i> , eds., New Generation Vaccines, Marcel Dekker, Inc., New York, pp. 161-188 (1990).
✓	C7	Curtiss <i>et al.</i> , Live Oral Avirulent <i>Salmonella</i> Vaccines, <i>Vet. Microbiol.</i> 37:397-405 (1993).
✓	C8	Curtiss <i>et al.</i> , Recombinant Avirulent <i>Salmonella</i> Vaccine Strains with Stable Maintenance and High Level Expression of Cloned Genes <i>in vivo</i> , <i>Immunol. Invest.</i> 18:583-596 (1989).
✓	C9	Donnenberg <i>et al.</i> , Construction of an <i>eae</i> Deletion Mutant of Enteropathogenic <i>Escherichia coli</i> by Using a Positive-Selection Suicide Vector, <i>Infect. and Immun.</i> 59:4310-4317 (1991).
✓	C10	Dunyak <i>et al.</i> , Identification of <i>Salmonella</i> Pathogenicity Island 2 (SPI2) Genes in <i>Salmonella choleraesuis</i> Signature-Tagged Mutagenesis, 97th General Meeting of the American Society for Microbiology, May 4-8, 1997, Miami Beach, Florida, American Society for Microbiology, Washington, D.C. (1997), p. 76. (ABSTRACT).
✓	C11	Galan <i>et al.</i> , Cloning and Characterization of the <i>asd</i> gene of <i>Salmonella typhimurium</i> : Use in Stable Maintenance of Recombinant Plasmids in <i>Salmonella</i> Vaccine Strains, <i>Gene</i> 94:29-35 (1990).

EXAMINER

MARK NAVARRO

DATE CONSIDERED

10/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

DEC 07 2001

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6114.NSerial No.
09/809,524

INFORMATION DISCLOSURE STATEMENT

Applicant
Lowery *et al.*Filing Date
March 15, 2001Group
1645

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

~	C12	GenBank Accession No. AJ224892, <i>Salmonella typhimurium</i> ssaE, sseA, sseB, sscA, sseC, sseD, sseE, sscB, sseF, sseG, ssaG, ssaH, ssaI genes and partial ssaD, ssaJ genes, Hensel, M., 1998.
~	C13	GenBank Accession No. U51927, <i>Salmonella typhimurium</i> SpiR and SpiB genes, partial cds, and SpiC and SpiA genes. complete cds, Groisman, E., 1996.
~	C14	GenBank Accession No. X99944, <i>Salmonella typhimurium</i> ssaQ, ssaR, ssaS, ssaT and ssaU genes, Hensel, M., 1997.
~	C15	GenBank Accession No. Y09357, <i>S. typhimurium</i> ssaJ, ssaK, ssaL, ssaM, ssaV, ssaN, ssaO, ssaP, ssaQ genes, Hensel, M. <i>et al.</i> , 1997.
~	C16	GenBank Accession No. Z95891, <i>S. typhimurium</i> ssrA and ssrB genes, Hensel, M., 1998.
~	C17	Germanier <i>et al.</i> , Immunity in Experimental Salmonellosis, II. Basis for the Avirulence and Protective Capacity of <i>gal E</i> Mutants, <i>Infect. and Immun.</i> 4:663-673 (1971).
~	C18	Hensel <i>et al.</i> , Analysis of the Boundaries of <i>Salmonella</i> Pathogenicity Island 2 and the Corresponding Chromosomal Region of <i>Escherichia coli</i> K-12, <i>J. Bacteriol.</i> 179:1105-1111 (1997).
~	C19	Hensel <i>et al.</i> , Functional analysis of <i>ssaI</i> and the <i>ssaK/U</i> operon, 13 genes encoding components of the type III secretion apparatus of <i>Salmonella</i> Pathogenicity Island 2, <i>Molec. Microbiol.</i> 24:155-167 (1997).
~	C20	Hohmann <i>et al.</i> , Intestinal and Serum Antibody Responses in Mice After Oral Immunization with <i>Salmonella</i> , <i>Escherichia coli</i> , and <i>Salmonella-Escherichia coli</i> Hybrid Strains, <i>Infect. and Immun.</i> 25:27-33 (1979).
~	C21	Hoiseth <i>et al.</i> , Aromatic-dependent <i>Salmonella typhimurium</i> Are Non-virulent and Effective as Live Vaccines, <i>Nature</i> 291:238-239 (1981).
~	C22	Hone <i>et al.</i> , Construction of Defined <i>galE</i> Mutants of <i>Salmonella</i> for Use as Vaccines, <i>J. Infect. Dis.</i> 156:167-174 (1987).

EXAMINER

MARK NAVARRO

DATE CONSIDERED

10/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
DEC 10 2001
TECH CENTER 1600/2900JUN 07 2002
TECH CENTER 1600/2900

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket No.
28341/6114.NSerial No.
09/809,524Applicant
Lowery *et al.*Filing Date
March 15, 2001Group
1645

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

~	C23	Horton <i>et al.</i> , Gene Splicing by Overlap Extension: Tailor-Made Genes Using the Polymerase Chain Reaction, <i>Biotechniques</i> 8:528-535 (1990).
~	C24	Kennedy <i>et al.</i> , Characterization and Protective Properties of Attenuated Mutants of <i>Salmonella dublin</i> , 97th General Meeting of the American Society for Microbiology, B-287:78 (1997).
~	C25	Letellier <i>et al.</i> , Assessment of various treatments to reduce carriage of <i>Salmonella</i> in swine, <i>The Canadian Journal of Veterinary Research</i> 64:27-31 (2000).
~	C26	Levine <i>et al.</i> , Safety, Infectivity, Immunogenicity, and In Vivo Stability of Two Attenuated Auxotrophic Mutant Strains of <i>Salmonella typhi</i> , 541Ty and 543Ty, as Live Oral Vaccines in Humans, <i>J. Clin. Invest.</i> 79:888-902 (1987).
~	C27	Lindberg <i>et al.</i> , Antibody Response and Protection against Challenge in Mice Vaccinated Intraperitoneally with a Live <i>aroA</i> O4-O9 Hybrid <i>Salmonella dublin</i> Strain, <i>Infect. and Immun.</i> 61:1211-1221 (1993).
~	C28	Linde <i>et al.</i> , Stable <i>Salmonella</i> Live Vaccine Strains with Two or More Attenuating Mutations and Any Desired Level of Attenuation, <i>Vaccine</i> 8:278-282 (1990).
~	C29	McFarland <i>et al.</i> , Effect of Different Purine Auxotrophic Mutations on Mouse-Virulence of a Vi-Positive Strain of <i>Salmonella dublin</i> and Two Strains of <i>Salmonella typhimurium</i> , <i>Microb. Pathogen.</i> 3:129-141 (1987).
~	C30	Mills <i>et al.</i> , A 40kb Chromosomal Fragment Encoding <i>Salmonella typhimurium</i> Invasion Genes Is Absent from the Corresponding Region of the <i>Escherichia coli</i> K-12 Chromosome, <i>Mol. Microbiol.</i> 5:749-759 (1995).
~	C31	Nnalue <i>et al.</i> , Some <i>galE</i> Mutants of <i>Salmonella choleraesuis</i> Retain Virulence, <i>Infect. and Immun.</i> 54:635-640 (1986).
~	C32	Nnalue <i>et al.</i> , Tests of the Virulence and Live-Vaccine Efficacy of Auxotrophic and <i>galE</i> Derivatives of <i>Salmonella choleraesuis</i> , <i>Infect. and Immun.</i> 55:955-962 (1987).

EXAMINER

MARK NARAYAN

DATE CONSIDERED

10/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

DEC 07 2001

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

28341/6114.N

Serial No.

09/809,524

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Lowery *et al.*

Filing Date

March 15, 2001

Group

1600

RECEIVED
DEC 10 2001
TECH CENTER 1600/2300

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

~	C33	O'Callaghan <i>et al.</i> , Characterization of Aromatic- and Purine-Dependent <i>Salmonella typhimurium</i> : Attenuation, Persistence, and Ability to Induce Protective Immunity in BALB/c Mice, <i>Infect. and Immun.</i> 56: 419-423(1988).
~	C34	O'Callaghan <i>et al.</i> , Immune Responses in BALB/c Mice Following Immunization with Aromatic Compound or Purine-Dependent <i>Salmonella typhimurium</i> Strains, <i>Immunology</i> 69:184-189 (1990).
~	C35	Ochman <i>et al.</i> , Identification of a pathogenicity island required for <i>Salmonella</i> survival in host cells, <i>Proc. Natl. Acad. Sci. (USA)</i> 93:7800-7804 (1996).
~	C36	Reyrat <i>et al.</i> , Counters selectable Markers: Untapped Tools for Bacterial Genetics and Pathogenesis, <i>Infect. and Immun.</i> 66:4011-4017 (1998).
~	C37	Robertsson <i>et al.</i> , <i>Salmonella typhimurium</i> Infection in Calves: Protection and Survival of Virulent Challenge Bacteria After Immunization with Live or Inactivated Vaccines, <i>Infect. and Immun.</i> 41:742-750 (1983).
~	C38	Shea <i>et al.</i> , Identification of a virulence locus encoding a second type III secretion system in <i>Salmonella typhimurium</i> , <i>Proc. Natl. Acad. Sci. (USA)</i> 93:2593-2597 (1996).
~	C39	Smith <i>et al.</i> , Vaccination of Calves with Orally Administered Aromatic-Dependent <i>Salmonella dublin</i> , <i>Am. J. Vet. Res.</i> 54:1249-1255 (1993).
~	C40	Smith <i>et al.</i> , Aromatic-dependent <i>Salmonella typhimurium</i> as Modified Live Vaccines for Calves, <i>Am. J. Vet. Res.</i> 45:59-66 (1984).
~	C41	Smith <i>et al.</i> , Aromatic-dependent <i>Salmonella dublin</i> as a Parenteral Modified Live Vaccine for Calves, <i>Am. J. Vet. Res.</i> 45:2231-2235 (1984).
~	C42	Tacket <i>et al.</i> , Comparison of the Safety and Immunogenicity of $\Delta aroC \Delta aroD$ and $\Delta cya \Delta crp$ <i>Salmonella typhi</i> Strains in Adult Volunteers, <i>Infect. and Immun.</i> 60:536-541 (1992).

EXAMINER


MARK NAVARRO

DATE CONSIDERED

10/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

28341/6114.N

Serial No.

09/809,524

Applicant

Lowery *et al.*

Filing Date

March 15, 2001

Group

1645

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED
DEC 10 2001
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

~	C43	Zhang <i>et al.</i> , An RNA Helicase, <i>RHIV-1</i> , Induced by Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is Mapped on Porcine Chromosome 10q13, <i>Microb. Pathogen</i> . 28:267-278(2000).
---	-----	--

RECEIVED
JUN 07 2002
TECH CENTER 1600/2900

EXAMINER

MARK NAVARRO

DATE CONSIDERED

10/16/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.